Insider Selling: uniQure (NASDAQ:QURE) Insider Sells $144,907.79 in Stock

uniQure N.V. (NASDAQ:QURE) insider Jeannette Potts sold 5,237 shares of the stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $27.67, for a total value of $144,907.79. Following the transaction, the insider directly owned 133,246 shares of the company’s stock, valued at $3,686,916.82. The trade was a 3.78% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

uniQure Stock Performance

QURE opened at $46.29 on Friday. uniQure N.V. has a 1-year low of $8.73 and a 1-year high of $71.50. The firm has a market capitalization of $2.92 billion, a price-to-earnings ratio of -13.30 and a beta of 0.98. The company has a debt-to-equity ratio of 0.33, a current ratio of 10.40 and a quick ratio of 10.40. The company’s 50 day simple moving average is $24.74 and its two-hundred day simple moving average is $22.20.

uniQure (NASDAQ:QURE) last posted its earnings results on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share for the quarter, beating the consensus estimate of ($0.88) by $0.03. uniQure had a negative net margin of 1,154.42% and a negative return on equity of 145.81%. The company had revenue of $3.56 million for the quarter, compared to analyst estimates of $5.21 million. Analysts expect that uniQure N.V. will post -3.64 EPS for the current fiscal year.

uniQure News Roundup

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: The FDA’s feedback now appears to support a near-term biologics license application for AMT-130, increasing the odds of accelerated approval for Huntington’s disease and boosting sentiment around uniQure’s lead program. Reuters
• Positive Sentiment: Barclays upgraded uniQure and raised its price target to $65 from $25, reflecting a more constructive view of the company after the FDA development. Benzinga
• Positive Sentiment: uniQure also announced preliminary AMT-260 data in refractory mesial temporal lobe epilepsy, saying the treatment was generally well tolerated with no serious adverse events so far and early signs of biological activity. GlobeNewswire
• Neutral Sentiment: Insider selling by a director and an executive has drawn attention, but the trades were disclosed and at least one was made under a pre-arranged 10b5-1 plan, so they are less likely to be interpreted as a fundamental warning sign.
• Neutral Sentiment: Several articles argue the stock may still be undervalued after the FDA update, but those calls mostly reflect optimism already fueled by the regulatory news rather than a new company-specific catalyst. Yahoo Finance

Analyst Ratings Changes

QURE has been the subject of several analyst reports. Wall Street Zen raised uniQure from a “sell” rating to a “hold” rating in a research report on Saturday, March 28th. Mizuho raised shares of uniQure from a “neutral” rating to an “outperform” rating and raised their price objective for the stock from $12.00 to $35.00 in a research report on Wednesday, March 11th. Sanford C. Bernstein lowered uniQure to a “market perform” rating in a report on Tuesday, March 3rd. Wells Fargo & Company upgraded shares of uniQure from an “equal weight” rating to an “overweight” rating and boosted their price target for the stock from $15.00 to $60.00 in a research note on Monday, March 9th. Finally, Stifel Nicolaus set a $28.00 price objective on uniQure in a research report on Tuesday, May 5th. Twelve analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $58.92.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the company. Woodline Partners LP raised its stake in shares of uniQure by 25.0% in the 1st quarter. Woodline Partners LP now owns 175,806 shares of the biotechnology company’s stock valued at $1,864,000 after acquiring an additional 35,175 shares during the period. Legal & General Group Plc acquired a new position in shares of uniQure in the 2nd quarter valued at approximately $497,000. Marshall Wace LLP raised its holdings in uniQure by 276.5% in the second quarter. Marshall Wace LLP now owns 222,979 shares of the biotechnology company’s stock valued at $3,108,000 after acquiring an additional 163,749 shares in the last quarter. California State Teachers Retirement System acquired a new stake in shares of uniQure in the 2nd quarter valued at about $540,000. Finally, Ameriprise Financial Inc. raised its stake in uniQure by 38.6% during the second quarter. Ameriprise Financial Inc. now owns 761,948 shares of the biotechnology company’s stock valued at $10,622,000 after buying an additional 212,218 shares in the last quarter. 78.83% of the stock is owned by hedge funds and other institutional investors.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.